IRINOTECAN INTAS irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial

Nchi: Australia

Lugha: Kiingereza

Chanzo: Department of Health (Therapeutic Goods Administration)

Viambatanisho vya kazi:

irinotecan hydrochloride trihydrate, Quantity: 300 mg

Inapatikana kutoka:

Accord Healthcare Pty Ltd

Dawa fomu:

Injection, concentrated

Tungo:

Excipient Ingredients: hydrochloric acid; sodium hydroxide; lactic acid; water for injections; sorbitol

Njia ya uendeshaji:

Intravenous Infusion

Vitengo katika mfuko:

1

Dawa ya aina:

(S4) Prescription Only Medicine

Matibabu dalili:

Irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Bidhaa muhtasari:

Visual Identification: A pale yellow clear solution; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Idhini hali ya:

Registered

Idhini ya tarehe:

2020-03-05